AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)
Corp Office: H.No 1769, Phase 3B2, Mohali-160059
Phone: 0172-5020758-69 Website: www.ajoonibiotech.com
E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com
CIN: L85190PB2010PLC040162

November 13, 2026

To,
National Stock Exchange of India Ltd
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400051

Dear Sir / Madam,

SUB: Outcome of the Board Meeting held on Friday, November 13, 2026, pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015.

SYMBOL: AJOONI

Dear Sir,

With reference to the above captioned subject, we wish to inform you that the Board of Directors of the Company held their meeting on Friday, 13th November 2026 at 10.30 a.m. and concluded at 12.30 p.m. at the Corporate Office of the company situated at House No. 1769, Phase 3B2, Mohali, Punjab. Following transactions were considered and approved:

1. Un-audited Financial Results for the quarter and half year ended September 30, 2026.
2. Limited Review Report from the auditor for the quarter and half year ended September 30, 2026.
3. Any other matter with the permission of the Chair.

Kindly take same on your records.

Thanking You,
Yours Truly,
For Ajooni Biotech Limited

SWATI VIJAN
Digitally signed by SWATI VIJAN
Date: 2026.11.13 12:38:13 +05'30'

Swati Vijan
Company Secretary
FCS13627

AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)
Corp Office: H.No 1769, Phase 3B2, Mohali-160059
Phone: 0172-5020758-69 Website: www.ajoonibiotech.com
E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com
CIN: L85190PB2010PLC040162

November 13, 2026

To,
National Stock Exchange of India Ltd
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400051

Dear Sir / Madam,

SYMBOL: AJOONI

Sub.: Approval of Un-Audited Financial Results for the quarter and half year ended 30th September 2026.

Dear Sir,

Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform that the Board of Directors of the Company at their meeting held on Friday, November 13, 2026 at the Corporate Office of the company have considered and approved the un-Audited Financial Statements for the quarter and half year ended on 30th September 2026. In these regards, we are enclosing herewith:

1. Un-Audited Financial Results for the quarter and half year ended on 30th September 2026 as recommended by the Audit Committee.
2. Limited Review Report from the auditor for the quarter and half year ended on 30th September 2026.

You are requested to kindly take the same on record.

Thanking You,
Yours Truly,
For Ajooni Biotech Limited

SWATI VIJAN
Digitally signed by SWATI VIJAN
Date: 2026.11.13 12:37:49 +05'30'

Swati Vijan
Company Secretary
FCS13627

AJOONI BIOTECH LIMITED

CIN : L85190PB2010PLC040162

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER 2026(In Lakhs)

	PARTICULARS	QUARTER ENDED					Year Ended (Audited)
		30.09.2026	30.06.2026	30.09.2025	Period Ended (UnAudited) 30.09.2026	Period Ended (UnAudited) 30.09.2025	31.03.2026
I	Income						
	Revenue from operations	6,536.95	6,349.07	3,173.51	12,886.02	6,300.28	18,237.81
	Other income	31.54	26.89	14.75	58.43	79.29	241.81
	Total income from operations	**6,568.49**	**6,375.96**	**3,188.26**	**12,944.45**	**6,379.57**	**18,479.62**
II	Expenses						
	Cost of Material Consumed	5,448.21	5,454.86	2,493.10	10,903.07	5,057.27	14,805.33
	Change In Inventories	42.53	(39.06)	6.78	3.47	2.60	(12.54)
	Employee benefit expenses	141.07	137.59	111.00	278.66	210.21	457.29
	Finance costs	71.13	48.21	17.21	119.34	25.67	72.94
	Depreciation and amortization expenses	91.99	80.27	24.54	172.26	49.37	220.63
	Payment to NSE						
	Other expenses	703.04	628.65	412.26	1,331.69	808.36	2,362.14
	Total expenses	**6,497.97**	**6,310.52**	**3,064.89**	**12,808.49**	**6,153.48**	**17,905.79**
III	**Profit/(Loss) before exceptional items and tax**	**70.52**	**65.44**	**123.37**	**135.96**	**226.09**	**573.83**
IV	**Exceptional items**						
V	**Profit/(Loss) before tax**	**70.52**	**65.44**	**123.37**	**135.96**	**226.09**	**573.83**
VI	Tax expenses						
	a) Current tax	17.75	18.62	32.08	36.37	54.58	153.01
	b) Deferred tax	1.67	3.64	1.92	5.31	(0.16)	11.37
	b) Mat Credit						
VII	**Net Profit/(Loss) for the period/year**	**51.10**	**43.18**	**93.21**	**94.28**	**171.35**	**432.19**
VIII	Other comprehensive income (net of tax)						

AJOONI BIOTECH LTD. MOHALI

	loss:						
					-	-	(120.94)
	Total other comprehensive income						
IX	Total comprehensive income for the period/year (VII+VIII)	51.10	43.18	93.21	94.28	171.35	(120.94)
X	Paid-up equity share capital (face value of the share shall be indicated)	3,624.87	3,444.87	3,444.87	3,624.87	3,444.87	311.10
XI	Other equity (excluding revaluation reserve)	5,719.37	5,717.45	5,456.23	5,762.55	5,534.37	3,444.87
XII	EPS in Rs. (Face Value of Rs.2/- each)*						5,674.27
	-Basic	0.02	0.01	0.08	0.05	0.10	0.25
	-Diluted	0.02	0.01	0.08	0.05	0.10	0.25

Notes:

1. The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 10.11.2026 after being reviewed by the Audit Committee.

2. The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.

3. Due to re-grouping of schedules, and as per applicability of IND-AS, there has been a difference in the figures as reported earlier.

For Ajooni Biotech Limited

Jasjot Singh
*Managing Director
DIN: 01937631

Place : Mohali
Date : 13/11/2026

Ajooni biotech

AJOONI BIOTECH LIMITED

Regd. Office : D-118, Industrial Area, Phase-VII, Mohali-160055 (Pb.)
Corporate office : H.No.1769, Phase 3B2, Mohali-160059
Phone : 0172-5020758-69 Website : www.ajoonibiotech.com
E-mail : ajooni.biotech@gmail.com / info@ajoonibiotech.com
CIN: L85190PB2010PLC040162

AJOONI BIOTECH LIMITED
CIN : L85190PB2010PLC040162

Statement of Assets and Liabilities
For the Year ended on 30th September 2026

in Rs. (Lakhs)

PARTICULARS	30TH September 2026	31ST MARCH 2026
I. ASSETS		
(1) Non - Current Assets		
a) Property, Plant and Equipment	3,255.22	2,585.58
b) Capital Work In Progress	0.00	0.00
c) Investment Property		-
d) Goodwill		-
e) Other Intangible Assets	29.96	35.95
f) Intangible Assets Under Development		-
g) Biological Assets other than Bearer Plants		-
h) Financial Assets		
(1) Investments	277.90	244.75
(2) Trade Receivables		-
(3) Loans		-
(4) Other Financial Assets	1,500.00	1,500.00
i) Deffered Tax Asset (net)	50.97	49.29
j) Other Non Current Asset	280.88	173.30
(2) Current Assets		
a) Inventories	3,030.44	3,945.51
b) Financial Assets		
(1) Investments		
(2) Trade Receivables	2,220.01	1,783.43
(3) Cash & Cash Equivalent	28.12	41.90
(4) Bank Balances other than (iii) above		
(5) Loans	1,602.84	1,414.92
(6) Other Financial Asset	53.62	69.98
c) Current Tax Assets (net)		-
d) Other Current Asset	888.03	191.91

AJOONI BIOTECH LTD. MOHALI

TOTAL	13,217.99	12,036.52
II EQUITY AND LIABILITIES		
(1) Equity		
a)Equity Share Capital	3,624.87	3,444.87
b) Other Equity	5,762.55	5,674.28
(2) Non-Current Liabilities		
a) Financial Liabilities		
(1) Borrowings	651.55	154.00
(2) Trade Payables		
(3) Other Financial Liabilties		
b) Employee Benefit Obligations	30.34	28.65
c) Deferred Tax Liability (net)		-
d) Other Non Current Liability		-
(3) Current Liabilities		
a) Financial Liabilities		
(1) Borrowings	2,627.96	1,622.28
(2) Trade Payables	468.61	891.41
(3) Other Financial Liabilities		
b) Employee Benefit Obligations	1.19	1.69
c) Other Current Liabilities	33.17	66.32
d) Current tax liabilities (Net)	17.75	153.01
TOTAL	13,217.99	12,036.51

Place : Mohali
Date : 13.11.2026

For Ajooni Biotech Limited

AJOONI BIOTECH LTD. MOHALI

Jasjot Singh
Managing Director
DIN: 01937631

Ajooni biotech

AJOONI BIOTECH LIMITED

Regd. Office : D-118, Industrial Area, Phase-VII, Mohali-160055 (Pb.)
Corporate office : H.No.1769, Phase 3B2, Mohali-160059
Phone : 0172-5020758-69 Website : www.ajoonibiotech.com
E-mail : ajooni.biotech@gmail.com / info@ajoonibiotech.com
CIN: L85190PB2010PLC040162

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED SEPTEMBER 30, 2026

	PARTICULARS			30TH SEPTEMBER 2026
"A" (1)	**CASH FLOW FROM OPERATING ACTIVITIES**			
	Profit/(Loss) Before Tax			135.96
	Adjustments for:			
	Depreciation & Amortization	172.26		
	Interest & Finance Charges	119.34		
	Interest Income	0.00	291.60	
	Operating Profit before Working Capital Changes			427.56
	Adjustments for:			
	Decrease/(Increase) in Receivables	-436.58		
	Decrease/(Increase) in Inventories	915.07		
	Decrease/(Increase) in Loans and Other Advances	-295.50		
	Decrease/(Increase) in Other Current Assets	-679.76		
	Increase/(Decrease) in Trade Payables	-426.14		
	Increase/(Decrease) in Other Current Liabilities	-33.65	-956.56	
	Cash generated from operations			(529.00)
	Tax paid prev year			
	Net Cash flow from Operating activities			(529.00)
	(2) CASH FLOW FROM INVESTING ACTIVITIES			
	Purchase of Tangible Assets/ Intangible Assets/ Capital Work-In-Progress		-841.91	
	(Increase)/Decreaseby sale/purchase in Non-Current Investmer		-445.44	
	Interest Income		0.00	
	Net Cash used in Investing activities			-1287.35
	(3) CASH FLOW FROM FINANCING ACTIVITIES			
	Proceeds from/ (Repayment) of Long term Borrowings		497.55	
	Proceeds from issue of share capital		180.00	
	premium received		0.00	
	Increase/(Decrease) in Short Term Borrowings		1,005.68	
	Interest and Other Finance Costs paid		119.34	
	Net Cash used in financing activities			1,802.57
"B"	Net increase in cash & Cash Equivalents			(13.78)
	Add: Cash and Cash equivalents at the Beginning of the Year 1.04.2026			41.90
"c"	Cash & Cash Equivalents at 30.09.2026			28.12

Place : Mohali
Date : 13/11/2026

For Ajooni Biotech Limited

Jasjot Singh
Managing Director
DIN: 01937631

NARINDER KUMAR AND COMPANY
CHARTERED ACCOUNTANTS

SCO 65-B (1st Floor) City Heart,
Kharar Chandigarh Road,
Kharar, SAS Nagar Mohali-140301
Mobile : 98154 50065
Email : nkgargca@yahoo.co.in

Limited Review Report

Ref. No. ..... Dated .....

Review Report to Board of Directors of M/s Ajooni Biotech Limited.

We have reviewed the accompanying statement of unaudited financial results of M/s Ajooni Biotech Limited having Regd. office at D-118, Industrial Area, Phase-VII, Mohali Punjab-160055. for the period ended 30th September 2026.(the Statement) attached herewith , being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations 2015 (as amended) . Including relevant circulars issued by the Securities and Exchange Board of India (SEBI) from time to Time.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For NARINDER KUMAR AND COMPANY
Chartered Accountants

NARINDER KUMAR & COMPANY
S.C.O. 65-B
(1st Floor), City Heart
Kharar Chandigarh Road
Kharar, Mohali-140301
FRN-003[illegible]N
Chartered Accountants

(NARINDER KUMAR GARG)
PARTNER
M.NO-080287
Date:-13.11.2026
UDIN:- 26080287LBGFJV1065